Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors
- 852 Downloads
Albumin-bound paclitaxel, ABI-007 (Abraxane®), has a different toxicity profile than solvent-based paclitaxel, including a lower rate of severe neutropenia. The combination of ABI-007 and carboplatin may have significant activity in a variety of tumor types including non-small and small cell lung cancer, ovarian cancer, and breast cancer. The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin.
Forty-one patients with solid tumors were enrolled, and received ABI-007 in combination with carboplatin AUC of 6 on day 1. Group A received ABI-007 at doses ranging from 220 to 340 mg/m2 on day 1 every 21 days; group B received ABI-007 at 100 or 125 mg/m2 on days 1, 8, and 15 every 28 days; and group C received ABI-007 125 or 150 mg/m2 on days 1 and 8 every 21 days. Dose-limiting toxicities were assessed after the first cycle. Doses were escalated in cohorts of three to six patients. Fifteen patients participated in a pharmacokinetic study investigating the effects of the sequence of infusion. ABI-007 was infused first followed by carboplatin in cycle 1, and vice versa in cycle 2.
The MTD of ABI-007 in combination with carboplatin was 300, 100, and 125 mg/m2 in groups A, B, and C, respectively. Myelosuppression was the primary dose limiting toxicity. No unexpected or new toxicities were reported. Sequence of infusion did not affect either the pharmacokinetics of ABI-007 or the degree of neutropenia. Responses were seen in melanoma, lung, bladder, esophageal, pancreatic, breast cancer, and cancer of unknown primary.
The recommended dose for phase II studies of ABI-007 in combination with carboplatin (AUC of 6) is 300, 100, 125 mg/m2 for the schedules A, B, and C, respectively. The combination of ABI-007 and carboplatin is well tolerated and active in this heavily pretreated patient population.
KeywordsDose-limiting toxicity Maximum tolerated dose Melanoma Non-small-cell lung cancer Small-cell lung cancer Clinical trial
The authors thank Paul E Jones, Tammy Allred, Susan Natoli and Henry Bell for their help with the study, and the patients whose participation made this trial possible. Financially supported by the Grant for General Clinical Research Center (Grant # RR00046) and Abraxis Bioscience.
- 7.Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21(17):3194–3200PubMedCrossRefGoogle Scholar
- 10.Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB et al (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer The European cancer centre. J Clin Oncol 15(1):317–329PubMedGoogle Scholar
- 12.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRefGoogle Scholar
- 16.Kosmidis P, Mylonakis N, Skarlos D, Samantas E, Dimopoulos M, Papadimitriou C et al (2000) Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic cooperative oncology group (HeCOG). Ann Oncol 11(7):799–805PubMedCrossRefGoogle Scholar
- 19.Allerton JP, Hagenstad CT, Webb RT, Smith GB, Birch R, Goggins TF et al (2006) A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol (ASCO Annual Meetings Proceedings) 24(18S):7127 (abstract)Google Scholar
- 20.Hawkins MJ, Georgy M, Makhson A, Cheporov S, Sergey O, Yablonsky P et al (2006) Dose escalation study of nab-paclitaxel followed by carboplatin a first line therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol (ASCO Annual Meetings Proceedings) 24(18S):7132 (abstract)Google Scholar
- 21.Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R et al (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20(5):1335–1343PubMedCrossRefGoogle Scholar